RUBY NASDAQ
Rubius Therapeutics, Inc.
1W: +185.0%
1M: +214.9%
3M: +251.8%
1Y: -76.2%
3Y: -99.3%
5Y: -99.6%
$0.06
Last traded 2023-12-29 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$178M
+8.3% ▲
Net Income
-$231M
-22.3% ▼
EPS (Diluted)
$-2.56
-19.1% ▼
EBITDA
-$170M
+39.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $52M | $112M | $116M | $142M | $96M |
| SG&A Expenses | $40M | $57M | $50M | $53M | $31M |
| Operating Expenses | $92M | $170M | $166M | $195M | $127M |
| Operating Income | -$92M | -$170M | -$166M | -$195M | -$178M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $464K | $3M | $4M | $6M | $4M |
| Income Before Tax | -$89M | -$163M | -$168M | -$197M | -$180M |
| Tax Expense | $0 | -$3M | -$6M | -$8M | $51M |
| Net Income | -$89M | -$160M | -$162M | -$189M | -$231M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.28 | $-2.04 | $-2.01 | $-2.15 | $-2.56 |
| EBITDA | -$92M | -$158M | -$158M | -$182M | -$170M |
| Shares Outstanding | 70M | 79M | 81M | 88M | 90M |